ClinicalTrials.gg
CompletedNCT01416636CTREPHUpdated Jun 7, 2022Results posted

Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)

A Phase 3 interventional study of Treprostinil sodium in Non-operable Chronic Thromboembolic Pulmonary Hypertension, sponsored by SciPharm SàRL. Completed at 6 sites in 4 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-06-07.

Sponsored by SciPharm SàRL · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.

Enrollment
10th of 37
105 · median 32
Started
2009
with 3 others
Phase 3
15 of 38
1 open now
Registered
17th of 38
by date
Lead sponsor
1 of 38
SciPharm SàRL

Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 10th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2009, is one of 15 in phase 3, and was the 17th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing treprostinil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine the effect on six-minute walking test (6MWT) distance after 24 weeks treatment with subcutaneous (SC) Treprostinil Sodium in patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension.

Read the detailed description

Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by non-resolving organized thromboembolic obstructing the pulmonary vascular bed. These thrombi are resistant to thrombolytic therapy and chronic plasmatic anticoagulation. An increase in pulmonary vascular resistance (PVR), right ventricular overload, and eventually right ventricular failure ensue.

The treatment of choice for CTEPH is pulmonary endarterectomy (PEA), providing a potential cure for the disease. However, about 50 % of patients are not candidates for surgery, mainly because of distal location of thromboemboli. Despite recent advances in the treatment of pulmonary arterial hypertension (PAH), medical treatments have not been recommended for inoperable CTEPH, because of the concept that a predominantly major vessel obstructive arteriopathy would not be suitable for vasodilators. Furthermore, a major drawback of i.v. prostacyclin therapy is the need for a permanent central venous access that increases the risk of infection (0.22-0.68 per patient per year), thrombosis and new major vessel thromboembolism.

03

Conditions studied

  • Non-operable Chronic Thromboembolic Pulmonary Hypertension
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Subject must be competent to understand the information given in the written and from the investigator and must sign and date the informed consent prior to any study mandated procedure.
  2. Subject must be at least 18 years of age and can be of any ethnical origin
  3. Women of child bearing potential must be surgically sterile or (amenorrhea for at least 12 months) or using an acceptable form of . Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used correctly such as, implants, injectables, oral contraceptive medications, sexual abstinence, or a vasectomised partner.
  4. Subject must have a current diagnosis of CTEPH, as defined by the following criteria:

    • A test result of perfusion scintigraphy and pulmonary angiography and/or multislice CT not older than 6 months, consistent with the diagnosis CTEPH. In case of recurrent PH after PEA, test results from before the surgery are acceptable if a typical specimen was harvested during PEA substantiating the diagnosis of CTEPH.
    • A right heart catheterization, not older than 6 months, consistent with the diagnosis CTEPH but specifically with a mean pulmonary artery pressure (PAPm) of > 25 mmHg, and a PVR of > 300 dyn.s.cm-5
    • At least three months of effective anticoagulation therapy (without improvement / to exclude subacute pulmonary emboli)
  5. Subject must have CTEPH classified as severe, as defined by the following criteria:

    • An un-encouraged 6MWT distance of between 150 and 400 meters
    • Classification in the WHO/ (NYHA) functional class III or IV
  6. The subject must not be suitable to undergo a PEA and is therefore defined as non-operable, due to at least one of the following reasons:

    • Clot is not accessible
    • Discrepancy between severity of PH and morphologic lesion
    • Subject is not a good surgical candidate for other reasons:

    PVR > 1500 dynes.s.cm-5 Age Comorbidity No functional lung parenchyma

    • Unsuccessful PEA in the past with residual/recurrent CTEPH
    • No consent for PEA given by subject
  7. Subject must be willing and able to follow all study procedures

Exclusion:

  1. Subject with any form of pulmonary arterial hypertension or any disease known to cause PAH (WHO Group I)
  2. Subjects with a total lung capacity (TLC) of \< 70% predicted or a forced expiratory volume/forced vital capacity (/FVC \< 50%)
  3. Subject who received any prostanoids, within the 30 days before screening or be scheduled to receive prostanoids during the course of the study
  4. Subject with a new type of chronic therapy (a different category of vasodilator or diuretic) for PAH added within the last month, except anticoagulants
  5. Subject with an increased risk for hemorrhage or stroke or with a major cardiovascular event during the past 6 months.
  6. Unstable subjects for any reason (according to the investigators discretion)
  7. Subject who received any medication within 30 days prior to the screening visit of this study or be scheduled to receive another investigational drug during the course of this study
  8. Subject with a known intolerance to any drug relevant for this trial, especially to Treprostinil sodium or prostanoids
  9. Subject with a history or suspicion of non compliance
  10. Subject who has any musculoskeletal disease or any other disease that would limit ambulation
  11. Subject with other cardiovascular, liver, renal, hematologic, gastrointestinal immunologic, endocrine, metabolic, or central nervous system disease that, in the opinion of the investigator, may adversely affect the safety of the subject and /or efficacy of the study drug or limit the lifespan of the subject
  12. Female who is considering pregnancy or who is pregnant and/or lactating
  13. Subject who is an investigator or any other team member involved directly or indirectly in the conduct of the clinical study.
  14. Subject who is an inmate of a psychiatric ward, prison or is suspected not to be able to give consent of his free will
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Active comparator
    Treprostinil sodium low dose - Arm I

    Arm I (low dose): Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and was kept stable for another 12 weeks. Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3. This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump.

    Drug: Treprostinil sodium

  • Experimental
    Treprostinil sodium high dose - Arm II

    Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and kept stable for another 12 weeks. Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3. This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump.

    Drug: Treprostinil sodium

Interventions

06

What researchers measure

Primary outcomes

  1. Change in 6-minute Walk Test Distance After 24 Weeks

    To determine the effect of subcutaneous Treprostinil sodium on 6-minute walk test distance after 24 weeks in patients with severe non-operable chronic thromboembolic pulmonary hypertension severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension Time frame of the 6-minute walk test: The 6-minute walk test was conducted at the following visits: * baseline (day 1) * Visit 6 (day 168) In case of missing values, Last-Observation-Carried-Forward imputation method was used. In such cases values documented at Visit 4 (day84) were used.

    Time frame: Baseline and 24 weeks

Secondary outcomes

  1. Number of Participants With Clinical Worsening

    Clinical worsening defined as a decrease of 6-minute walk test distance of more than 20% from baseline due to Chronic Thromboembolic Pulmonary Hypertension, decrease of New York Heart Association functional class, hospitalization with the requirement for additional Pulmonary Hypertension specific treatment and/or death due to worsening Chronic Thromboembolic Pulmonary Hypertension. Clinical Worsening was assessed after 12 weeks and 24 weeks, participants experiencing clinical worsening at any time-point are reported.

    Time frame: 12 weeks and 24 weeks

  2. Effect on Maximal Borg Score During 6-minutes Walk Test

    The Borg scale was used for rating of dyspnea during 6-minutes walk test. The scale is defined from 0 to \> 10 (upper bound) (0 = NOTHING AT ALL; 0.5 = VERY VERY SLIGHT (just noticeable); 1 = VERY SLIGHT; 2 = SLIGHT; 3 = MODERATE; 4 = SOMEWHAT SEVERE; 5 = SEVERE; 6-9 = VERY SEVERE; 10 = VERY VERY SEVERE (almost maximum); \>10 MAXIMUM). As can be seen with the scale, the higher scale values represent a worse outcome. As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 48 patients in low dose group.

    Time frame: Baseline and 24 weeks

  3. Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class

    Class I - Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II - Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III - Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope Class IV - Patients with pulmonary hypertension in the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

    Time frame: Baseline and 24 weeks

  4. Effect on Quality of Life by the MINNESOTA Questionnaire

    This questionnaire is composed of 21 questions relating to limitations in lifestyle associated with Heart Failure. Respondents use a 5-point scale that ranges from 0 (none) to 5 (too much), with a score of 0 representing no limitation and a score of 5 representing maximum limitation. The change in individual score sum was evaluated and is displayed in the results, with a possible range of 0-105. Higher values indicate more limitations in Quality of Life. As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 50 patients randomized to high dose group and 46 patients in low dose group.

    Time frame: Baseline and 24 weeks

  5. Effect on N-terminal Pro-BNP Levels

    baseline values, assessment after 12 and 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 46 patients randomized to high dose group and 46 patients in low dose group.

    Time frame: Baseline and 24 weeks

  6. Effect on Hemodynamic Parameter (PVR - Pulmonary Vascular Resistance)

    baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.

    Time frame: Baseline and 24 weeks

  7. Effect on Hemodynamic Parameter (CI - Cardiac Index)

    baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.

    Time frame: Baseline and 24 weeks

  8. Effect on Hemodynamic Parameter (CO - Cardiac Output)

    baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.

    Time frame: Baseline and 24 weeks

  9. Effect on Hemodynamic Parameter (mPAP - Mean Pulmonary Arterial Pressure)

    baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 47 patients randomized to high dose group and 47 patients in low dose group.

    Time frame: Baseline and 24 weeks

  10. Effect on Hemodynamic Parameter (mRap - Mean Right Atrial Pressure)

    baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.

    Time frame: Baseline and 24 weeks

  11. Effect on Signs & Symptoms of the CTEPH

    baseline values, assessment after 24 weeks

    Time frame: Baseline and 24 weeks

07

Results

Posted Jun 10, 2019

Participant flow

Participant flow — Overall Study
MilestoneTreprostinil Sodium High Dose (~30ng/kg/Min)Treprostinil Sodium Low Dose (~3ng/kg/Min)
Started5352
Completed4546
Not completed86

Outcome measures

PrimaryChange in 6-minute Walk Test Distance After 24 Weeks

To determine the effect of subcutaneous Treprostinil sodium on 6-minute walk test distance after 24 weeks in patients with severe non-operable chronic thromboembolic pulmonary hypertension severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension Time frame of the 6-minute walk test: The 6-minute walk test was conducted at the following visits: * baseline (day 1) * Visit 6 (day 168) In case of missing values, Last-Observation-Carried-Forward imputation method was used. In such cases values documented at Visit 4 (day84) were used.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · m
Change in 6-minute Walk Test Distance After 24 Weeks
mHigh DoseLow Dose
Change in 6-minute Walk Test Distance After 24 Weeks45.43 ± 71.293.83 ± 56.21
Statistical analysis
  • High Dose vs Low Dose · ANCOVA · p = 0.002
  • High Dose vs Low Dose · Wilcoxon (Mann-Whitney) · p = 0.0003
SecondaryNumber of Participants With Clinical Worsening

Clinical worsening defined as a decrease of 6-minute walk test distance of more than 20% from baseline due to Chronic Thromboembolic Pulmonary Hypertension, decrease of New York Heart Association functional class, hospitalization with the requirement for additional Pulmonary Hypertension specific treatment and/or death due to worsening Chronic Thromboembolic Pulmonary Hypertension. Clinical Worsening was assessed after 12 weeks and 24 weeks, participants experiencing clinical worsening at any time-point are reported.

Time frame:
12 weeks and 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinical Worsening
ParticipantsHigh DoseLow Dose
Number of Participants With Clinical Worsening712
Statistical analysis
  • High Dose vs Low Dose · Wilcoxon (Mann-Whitney) · p = 0.605
SecondaryEffect on Maximal Borg Score During 6-minutes Walk Test

The Borg scale was used for rating of dyspnea during 6-minutes walk test. The scale is defined from 0 to \> 10 (upper bound) (0 = NOTHING AT ALL; 0.5 = VERY VERY SLIGHT (just noticeable); 1 = VERY SLIGHT; 2 = SLIGHT; 3 = MODERATE; 4 = SOMEWHAT SEVERE; 5 = SEVERE; 6-9 = VERY SEVERE; 10 = VERY VERY SEVERE (almost maximum); \>10 MAXIMUM). As can be seen with the scale, the higher scale values represent a worse outcome. As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 48 patients in low dose group.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · units on a scale
Effect on Maximal Borg Score During 6-minutes Walk Test
units on a scaleHigh DoseLow Dose
Effect on Maximal Borg Score During 6-minutes Walk Test-0.44 ± 2.21-0.13 ± 2.43
Statistical analysis
  • High Dose vs Low Dose · Wilcoxon (Mann-Whitney) · p = 0.307
SecondaryChange in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class

Class I - Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II - Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III - Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope Class IV - Patients with pulmonary hypertension in the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

Time frame:
Baseline and 24 weeks
Reported as:
Count of participants · Participants
Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class
ParticipantsHigh DoseLow Dose
Improved279
No change2236
Worse23
Not done24
Statistical analysis
  • High Dose vs Low Dose · Chi-squared · p = 0.0019
SecondaryEffect on Quality of Life by the MINNESOTA Questionnaire

This questionnaire is composed of 21 questions relating to limitations in lifestyle associated with Heart Failure. Respondents use a 5-point scale that ranges from 0 (none) to 5 (too much), with a score of 0 representing no limitation and a score of 5 representing maximum limitation. The change in individual score sum was evaluated and is displayed in the results, with a possible range of 0-105. Higher values indicate more limitations in Quality of Life. As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 50 patients randomized to high dose group and 46 patients in low dose group.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · units on a scale
Effect on Quality of Life by the MINNESOTA Questionnaire
units on a scaleHigh DoseLow Dose
Effect on Quality of Life by the MINNESOTA Questionnaire-6.36 ± 22.9-4.63 ± 19.34
Statistical analysis
  • High Dose vs Low Dose · Wilcoxon (Mann-Whitney) · p = 0.557
SecondaryEffect on N-terminal Pro-BNP Levels

baseline values, assessment after 12 and 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 46 patients randomized to high dose group and 46 patients in low dose group.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · percentage change to baseline
Effect on N-terminal Pro-BNP Levels
percentage change to baselineHigh DoseLow Dose
Effect on N-terminal Pro-BNP Levels0.84 ± 63.3241.68 ± 104.2
Statistical analysis
  • High Dose vs Low Dose · Wilcoxon (Mann-Whitney) · p = 0.032
SecondaryEffect on Hemodynamic Parameter (PVR - Pulmonary Vascular Resistance)

baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · dyn.s.cm^-5
Effect on Hemodynamic Parameter (PVR - Pulmonary Vascular Resistance)
dyn.s.cm^-5High DoseLow Dose
Effect on Hemodynamic Parameter (PVR - Pulmonary Vascular Resistance)-214.23 ± 324.2872.96 ± 284.95
Statistical analysis
  • High Dose vs Low Dose · Wilcoxon (Mann-Whitney) · p = 0.00001
SecondaryEffect on Hemodynamic Parameter (CI - Cardiac Index)

baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · L/min/m2
Effect on Hemodynamic Parameter (CI - Cardiac Index)
L/min/m2High DoseLow Dose
Effect on Hemodynamic Parameter (CI - Cardiac Index)0.42 ± 0.9-0.16 ± 0.54
Statistical analysis
  • High Dose vs Low Dose · Wilcoxon (Mann-Whitney) · p = 0.000003
SecondaryEffect on Hemodynamic Parameter (CO - Cardiac Output)

baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · L/min
Effect on Hemodynamic Parameter (CO - Cardiac Output)
L/minHigh DoseLow Dose
Effect on Hemodynamic Parameter (CO - Cardiac Output)0.63 ± 1.47-0.22 ± 1.06
Statistical analysis
  • High Dose vs Low Dose · Wilcoxon (Mann-Whitney) · p = 0.00008
SecondaryEffect on Hemodynamic Parameter (mPAP - Mean Pulmonary Arterial Pressure)

baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 47 patients randomized to high dose group and 47 patients in low dose group.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · mmHg
Effect on Hemodynamic Parameter (mPAP - Mean Pulmonary Arterial Pressure)
mmHgHigh DoseLow Dose
Effect on Hemodynamic Parameter (mPAP - Mean Pulmonary Arterial Pressure)-3.36 ± 8.04-0.4 ± 6.87
Statistical analysis
  • High Dose vs Low Dose · Wilcoxon (Mann-Whitney) · p = 0.04
SecondaryEffect on Hemodynamic Parameter (mRap - Mean Right Atrial Pressure)

baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · mmHg
Effect on Hemodynamic Parameter (mRap - Mean Right Atrial Pressure)
mmHgHigh DoseLow Dose
Effect on Hemodynamic Parameter (mRap - Mean Right Atrial Pressure)0.65 ± 5.082.87 ± 6.82
Statistical analysis
  • High Dose vs Low Dose · Wilcoxon (Mann-Whitney) · p = 0.227
SecondaryEffect on Signs & Symptoms of the CTEPH

baseline values, assessment after 24 weeks

Time frame:
Baseline and 24 weeks
Reported as:
Number · participants
Effect on Signs & Symptoms of the CTEPH
participantsHigh DoseLow Dose
Ascites : Baseline23
Ascites : Week 2413
Nausea/Vomiting : Baseline49
Nausea/Vomiting : Week 2459
Chest pain : Baseline1311
Chest pain : Week 2483
Orthopnoea : Baseline99
Orthopnoea : Week 2435
Dizziness : Baseline2521
Dizziness : Week 241110
Palpitations : Baseline1918
Palpitations : Week 24911
Dyspnoea at rest : Baseline710
Dyspnoea at rest : Week 24310
Paroxysmal nocturnal dyspnoea : Baseline71
Paroxysmal nocturnal dyspnoea : Week 2443
Dyspnoea on exertion : Baseline5351
Dyspnoea on exertion : Week 244643
Syncope : Baseline36
Syncope : Week 2412
Fatigue : Baseline3337
Fatigue : Week 242627
Thirst : Baseline1221
Thirst : Week 241213

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High Dose2/53 (3.8%)9/53 (17%)53/53 (100%)
Low Dose1/52 (1.9%)10/52 (19.2%)51/52 (98.1%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventHigh DoseLow Dose
Right ventricular failureCardiac disorders6/531/52
Cardiac failureCardiac disorders2/531/52
DyspneaCardiac disorders0/531/52
SyncopeCardiac disorders0/531/52
DiarrhoeaGastrointestinal disorders0/531/52
NauseaGastrointestinal disorders0/531/52
Incarcerated herniaGeneral disorders0/531/52
AppendicitisInfections and infestations0/531/52
Escherichia bacteraemiaInfections and infestations0/531/52
HypokalaemiaMetabolism and nutrition disorders0/531/52
Most frequent other events
Showing 10 of 19
Most frequent other events
EventHigh DoseLow Dose
Infusion site painGeneral disorders39/5342/52
DiarrhoeaGastrointestinal disorders33/5312/52
Infusion site reactionsGeneral disorders25/5324/52
HeadacheNervous system disorders12/534/52
Pain in extremitiesMusculoskeletal and connective tissue disorders11/531/52
Oedema peripheralCardiac disorders7/5310/52
NasopharyngitisInfections and infestations4/5310/52
Worsening of Pulmonary HypertensionVascular disorders3/538/52
Decreased appetiteGeneral disorders7/530/52
HypokalaemiaMetabolism and nutrition disorders4/535/52

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)High DoseLow DoseTotal
<=18 years011
Between 18 and 65 years152641
>=65 years382563
Age, Continuous
Age, Continuous(years)High DoseLow DoseTotal
Mean68.06 ± 11.1660.58 ± 14.5964.35 ± 13.44
Sex: Female, Male
Sex: Female, Male(Participants)High DoseLow DoseTotal
Female193049
Male342256
Region of Enrollment
Region of Enrollment(participants)High DoseLow DoseTotal
Austria282654
Czechia171734
Poland8816
Germany011
08

Study locations

6 sites
  • Krankenhaus der Elisabethinen
    Linz, 4020, Austria
  • Medical University of Vienna AKH - Division Cardiology
    Vienna, Austria
  • II. interní klinika Všeobecná fakultní nemocnice
    Prague, Czechia
  • Medical University Carl Gustav Carus Medizinische Klinik und Poliklinik I Medizinische Fakultät der Technischen Universität Dresden
    Dresden, Germany
  • Department of Cardiac and Vascular Diseases Centre for Rare Cardiovascular Diseases John Paul II Hospital
    Krakow, 31-202, Poland
  • NZOZ Europejskie Centrum Zdrowia Otwock
    Otwock, 05-400, Poland
09

References and documents

Publications

  • Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation. 1994 Jun;89(6):2715-21. doi: 10.1161/01.cir.89.6.2715. PubMed 8205686 ↗
  • Klepetko W, Mayer E, Sandoval J, Trulock EP, Vachiery JL, Dartevelle P, Pepke-Zaba J, Jamieson SW, Lang I, Corris P. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):73S-80S. doi: 10.1016/j.jacc.2004.02.039. PubMed 15194182 ↗
  • McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, Ahearn G; American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul;126(1 Suppl):78S-92S. doi: 10.1378/chest.126.1_suppl.78S. PubMed 15249497 ↗
  • Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2003 Feb 15;167(4):580-6. doi: 10.1164/rccm.200204-333OC. Epub 2002 Nov 21. PubMed 12446266 ↗
  • Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, Halank M, Simkova I, Karlocai K, Steringer-Mascherbauer R, Samarzija M, Salobir B, Klepetko W, Lindner J, Lang IM. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med. 2019 Mar;7(3):239-248. doi: 10.1016/S2213-2600(18)30367-9. Epub 2018 Nov 23. PubMed 30477763 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Nov 2016 and a completion of Apr 2021. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2019, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2011
First posted
Aug 15, 2011
Start
Mar 2009
Primary completionActual
Nov 2016
CompletionActual
Apr 2021
Results first posted
Jun 10, 2019
Last update
Jun 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01416636
Lead sponsor
SciPharm SàRL
Responsible party
Sponsor
First posted
Aug 15, 2011
Start date
Mar 2009
Primary completion
Nov 2016
Completion
Apr 2021
Results posted
Jun 10, 2019
Last update
Jun 7, 2022

Study contacts

Irene Lang, MD
principal investigator · Medical University Vienna

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion